TrialCompass TCL
Back to results
RecruitingPriority 4 · Lower priorityNCT07003100

A Prospective, US-based Study Assessing Mogamulizumab-associated Rash in Patients Diagnosed With Mycosis Fungoides or Sezary Syndrome and Treated With Standard of Care Mogamulizumab

ClinicalTrials.gov

Plain-language summary

This trial is testing Non-Interventional Study for people whose cutaneous T-cell lymphoma (skin lymphoma) has come back or has not responded to previous treatment. The study measures how well this treatment works and monitors for side effects. It is available at 10 US locations across multiple states.

Who can join (key eligibility)

  • Age 18 Years or older
  • Lymphoma came back or did not respond to prior treatment

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

Non-Interventional Study (OTHER): Non-interventional study

Drugs / treatments
Non-Interventional Study
Treatment length
Ask the trial team for details
Visit frequency
Ask the trial team for details
TrialCompass — Clinical Trial Summary

A Prospective, US-based Study Assessing Mogamulizumab-associated Rash in Patients Diagnosed With Mycosis Fungoides or Sezary Syndrome and Treated With Standard of Care Mogamulizumab

NCT07003100

Phase: | Status: Recruiting | Priority: Lower

Plain-language summary

This trial is testing Non-Interventional Study for people whose cutaneous T-cell lymphoma (skin lymphoma) has come back or has not responded to previous treatment. The study measures how well this treatment works and monitors for side effects. It is available at 10 US locations across multiple states.

Who can join

  • Age 18 Years or older
  • Lymphoma came back or did not respond to prior treatment

What's being tested

Non-Interventional Study (OTHER): Non-interventional study

Drugs / treatments: Non-Interventional Study

Treatment length: Ask the trial team for details

Visit frequency: Ask the trial team for details

Trial design

Non-randomized, blind

Enrollment target: 100 patients

Primary endpoint: Binary incidence of mogamulizumab-associated rash (MAR)

Ages: 18 Years to —

Start date: 2024-12-06 | Est. completion: 2026-10-19

Locations

10 US sites · 10 total

California, Florida, Georgia, Maryland, Massachusetts, Missouri, Pennsylvania, Texas, Washington

Contact

—

Sponsor: City of Hope Medical Center (OTHER)

Tags

CTCL · Relapsed/Refractory

View on ClinicalTrials.gov

https://clinicaltrials.gov/study/NCT07003100

Prepared using TrialCompass (trialcompass.com) on June 19, 2026. For informational purposes only. Always discuss with your healthcare team.